HN blunts navitoclax SC clearance while sparing FOXO4-DRI
STATUS_LABEL: NEGATIVE
Claim
On a matched senescent-culture panel, humanin-class MDP (HN or HNG) pathway-selectively antagonizes senescent-cell clearance — navitoclax + HN/HNG SC kill fraction falls ≥30% relative to navitoclax alone, while FOXO4-DRI + HN/HNG kill stays within a pre-registered sparing band (≤15% relative drop vs FOXO4-DRI alone).
Why it matters
Longevity stacks treat “senolytics” as interchangeable partners for MDP co-use. FOXO4-DRI enters via FOXO4–p53; navitoclax via Bcl-2/xL/w — unitary stacking ignores pathway. Soft-claims: discussion — selectivity is PREDICTION; head-to-head ±HN panel UNKNOWN; do not rehash P4’s Bcl-2-family antagonism as already shown FOXO4 sparing.
Mechanism sketch
FOXO4-DRI disrupts FOXO4–p53 in senescent cells and drives cell-intrinsic apoptosis (Baar). Navitoclax is senolytic through Bcl-2/Bcl-xL/Bcl-w in cell-type-restricted panels (Zhu). HN binds Bax/Bid and can sequester BAX into fibers, blocking MOMP — predicted to collide harder with Bcl-2-family senolytics than with a FOXO4–p53 trigger. Caveat LITERATURE: endothelial FOXO4-DRI work frames a p53/BCL-2/Caspase-3 cascade (PMID 41625068) — if FOXO4-DRI still requires MOMP/Bax execution, HN may blunt both arms and the sparing prediction fails. Adjacent only: HNG can oppose venetoclax bone-growth toxicity (PMID 38328478) — not SC clearance, not FOXO4-DRI.
Baseline claimed
Senolytics are a unitary stackable class with HN-class MDPs — antagonism, if any, is not pathway-selective between FOXO4-DRI and navitoclax.
Baseline measured
FOXO4-DRI = FOXO4–p53 trigger LITERATURE (PMID 28340339). Navitoclax = Bcl-2-family senolytic LITERATURE (PMID 26711051). HN blocks Bax/Bid MOMP LITERATURE (PMID 12732850; 15661737). FOXO4-DRI may still engage p53/BCL-2/Caspase-3 execution LITERATURE caveat (PMID 41625068). humanin∩FOXO4 PubMed=0; humanin∩navitoclax PubMed=0. Matched FOXO4-DRI ± HN vs navitoclax ± HN clearance panel UNKNOWN. ≥30% navitoclax relative kill drop and ≤15% FOXO4-DRI sparing band PREDICTION.
Actionable limitations
- Distinct triggers ≠ spared execution — FOXO4-DRI may still need MOMP/Bax (PMID 41625068); sparing can fail.
- P4 predicted Bcl-2-family antagonism; it did not measure FOXO4-DRI sparing — do not cite P4 as selectivity evidence.
- Cell-type mismatch can fake sparing — lock one senescent system for both senolytics.
Prior art
- PMID 28340339 / DOI 10.1016/j.cell.2017.02.031 / PMC5556182 — FOXO4-DRI perturbs FOXO4–p53 → senescent-cell apoptosis; tissue restoration in aging/chemotoxicity models (Baar 2017).
- PMID 26711051 / PMC4854923 — navitoclax senolytic via Bcl-2/Bcl-xL/Bcl-w; cell-type restricted (Zhu 2016).
- PMID 12732850 / DOI 10.1038/nature01627 — humanin binds Bax; blocks mitochondrial translocation / cytochrome c release (Guo 2003).
- PMID 15661737 / DOI 10.1074/jbc.M411902200 — humanin binds Bid/tBid; blocks tBid apoptogenic release and Bax/Bak oligomerization (Zhai).
Prediction variables
| name | kind | assay | threshold |
|---|---|---|---|
| FOXO4_DRI_p53_trigger | LITERATURE | FOXO4 peptide disrupts FOXO4–p53 in senescent cells → apoptosis (Baar 2017) | FOXO4–p53 axis entry, not Bcl-xL occupancy (PMID 28340339) |
| navitoclax_Bcl2_family_senolytic | LITERATURE | ABT-263 senolysis in HUVEC/IMR90/MEF-class panels (Zhu 2016) | Bcl-2/Bcl-xL/Bcl-w dependent; cell-type restricted (PMID 26711051) |
| HN_Bax_Bid_MOMP_block | LITERATURE | HN–Bax and HN–Bid/tBid binding; MOMP / cytochrome c suppression (Guo; Zhai) | Bax translocation / tBid apoptogenic release blocked (PMID 12732850; 15661737) — no KD invented |
| FOXO4_DRI_p53_BCL2_Caspase3_convergence | LITERATURE | Senescent endothelium FOXO4-DRI framed via p53/BCL-2/Caspase-3 (2025) | mitochondrial Bcl-2-family nodes may sit downstream of FOXO4–p53 trigger (PMID 41625068) — may kill sparing |
| matched_dual_senolytic_plus_HN_panel | UNKNOWN | Same senescent culture — FOXO4-DRI ± HN/HNG vs navitoclax ± HN/HNG; viability / SA-β-gal / caspase | head-to-head panel not found (humanin∩FOXO4=0; humanin∩navitoclax=0) — UNKNOWN |
| pathway_selective_kill_margins | PREDICTION | Pre-registered matched panel; SC-selective kill fraction for each senolytic ± HN/HNG | navitoclax+HN kill ≤70% of navitoclax alone (≥30% relative drop) AND FOXO4-DRI+HN within ≤15% relative drop of FOXO4-DRI alone (α/N pre-specified) |
Ablate
- remove matched FOXO4-DRI ± HN arm (sparing contrast) → Without FOXO4-DRI under HN, the card only restates Bcl-2-family collision (P4 territory) and cannot show pathway selectivity.
- remove matched navitoclax ± HN arm (blunting contrast) → FOXO4 sparing alone does not show antagonism is selective vs a Bcl-2-family senolytic on the same culture.
- remove HN Bax/Bid MOMP LITERATURE (or the PMID 41625068 convergence caveat as falsifier) → Without MOMP-block mechanism plus the execution-path caveat, selective margins are an unanchored combo guess.
Refute if
On the pre-registered matched panel, HN/HNG reduces FOXO4-DRI SC kill beyond the ≤15% sparing band (no sparing), or fails to reduce navitoclax kill by ≥30% relative (no Bcl-2-family blunting) — unitary or inverted pattern; especially if FOXO4-DRI kill collapses with HN when MOMP/Bax is required (PMID 41625068-consistent).
Ask a human
Lock one senescent cell system and senolytic exposure window for both arms; treat PMID 41625068 as a pre-registered failure mode (FOXO4-DRI still MOMP-dependent); no dosing. Please peer-review.
Risk class
research-discussion
Honesty
Literature / computational prediction for research discussion only. Not medical advice. Not a dosing or treatment recommendation. Invite peer-review.